Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition

[1]  M. Thun,et al.  Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen , 2010, International journal of cancer.

[2]  E. Løkkegaard,et al.  Hormone therapy and ovarian cancer. , 2009, JAMA.

[3]  M. Pike,et al.  Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin , 2009, Cancer.

[4]  Bin Wang,et al.  Hormone replacement therapy and ovarian cancer risk: a meta-analysis. , 2008, Gynecologic oncology.

[5]  A. Trentham-Dietz,et al.  Hormone therapy and ovarian cancer: incidence and survival , 2008, Cancer Causes & Control.

[6]  V. Beral,et al.  Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls , 2008, The Lancet.

[7]  N. Weiss,et al.  Menopausal Hormone Therapy and Risk of Epithelial Ovarian Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[8]  E. Greiser,et al.  Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. , 2007, Human reproduction update.

[9]  A. Kaunitz.  Menopausal Hormone Therapy and Ovarian Cancer Risk , 2007 .

[10]  V. Beral.  Ovarian cancer and hormone replacement therapy in the Million Women Study , 2007, The Lancet.

[11]  A. Paganini-Hill,et al.  Comparison of patient recall of hormone therapy with physician records , 2007, Menopause.

[12]  G. Colditz,et al.  A prospective study of postmenopausal hormone use and ovarian cancer risk , 2006, British Journal of Cancer.

[13]  P. Hartge,et al.  Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. , 2006, Journal of the National Cancer Institute.

[14]  A. Berchuck,et al.  Menopausal hormones and risk of ovarian cancer. , 2005, American journal of obstetrics and gynecology.

[15]  S. Ho,et al.  Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells , 2005, Oncogene.

[16]  B. Thomsen,et al.  Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. , 2004, Archives of internal medicine.

[17]  A. Eggen,et al.  Hormone replacement therapy and incidence of hormone‐dependent cancers in the Norwegian Women and Cancer study , 2004, International journal of cancer.

[18]  F. Clavel-Chapelon,et al.  Body size and breast cancer risk: Findings from the European prospective investigation into cancer and nutrition (EPIC) , 2004, International journal of cancer.

[19]  S. Nilsson,et al.  Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies , 2004, Acta obstetricia et gynecologica Scandinavica.

[20]  M. Pike,et al.  Erratum: Hormonal factors and the risk of invasive ovarian cancer: A population-based case-control study (Fertility and Sterility (2004) 82:1 (186-195)) , 2004 .

[21]  P. Pujol,et al.  Estrogens and epithelial ovarian cancer. , 2004, Gynecologic oncology.

[22]  M. Pike,et al.  Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. , 2004, Fertility and sterility.

[23]  F. Stanczyk.  All progestins are not created equal , 2003, Steroids.

[24]  Ana Maria Lopez,et al.  Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. , 2003, JAMA.

[25]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[26]  P. Dickman,et al.  Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. , 2002, American journal of epidemiology.

[27]  J. Weissfeld,et al.  Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. , 2002, Gynecologic oncology.

[28]  P. Hartge,et al.  Menopausal hormone replacement therapy and risk of ovarian cancer. , 2002, JAMA.

[29]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[30]  S. Mok,et al.  Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. , 2001, Cancer research.

[31]  V. Beral,et al.  Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. , 2001, Journal of epidemiology and biostatistics.

[32]  N. Hacker,et al.  Hormone replacement therapy and risk of epithelial ovarian cancer , 1999, British Journal of Cancer.

[33]  Shuk-Mei Ho,et al.  Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells , 1999 .

[34]  S. Mok,et al.  Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  L. Mcgowan.  Epidemiology of ovarian cancer. , 1989, Oncology.

[36]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .

[37]  R. Weller,et al.  International Histological Classification of Tumours , 1981 .

[38]  O. Dodge,et al.  The Effects of Arginine Deficiency on Lymphoma Cells , 1974, British Journal of Cancer.